GSK investors opt for anonymity in face of animal extremist threat
May 30, 2006Sales and Marketing
GlaxoSmithKline shareholders are using an administrative loophole to protect themselves in the face of a threatening letter campaign by animal …
Acomplia poised for approval as NHS focuses on fighting fat
May 30, 2006Sales and Marketing
Acomplia, the first-of-a-kind weight-loss drug, is set to gain approval across Europe within the coming weeks, offering a new hope …
NICE set to recommend new ‘gold standard’ treatments for early-stage breast cancer
May 30, 2006Three early breast cancer drugs are a step closer to overtaking the current gold standard treatment, after preliminary recommendation from …
Ringing the changes in pharmaceutical sales
May 25, 2006Sales and Marketing
Every business and every market is unique, but there is a huge expanse of common ground when it comes to …
Pharmacists given new guidance on counterfeit medicines
May 24, 2006Manufacturing and Production
Pharmacists have been asked to keep an eye out for suspected counterfeit medicines as part of a new awareness-raising initiative.Pharmacists' …
Pfizer’s insomnia treatment hit by ruling
May 24, 2006Sales and Marketing
A new insomnia treatment developed by Pfizer and Neurocrine Biosciences has suffered a setback after US regulators said a high-dose …
Phytopharm looks for licensing partner for Alzheimer drug
May 24, 2006Research and Development
Specialist pharma company Phytopharm says it is confident of finding a partner to develop and market one of its lead …
Exelon is first drug for Parkinson’s disease dementia
May 24, 2006Research and Development
Exelon has been launched as the first ever treatment for mild to moderately severe dementia associated with idiopathic Parkinson's disease.The …
PCTs hiding behind NICE decision over drug, says blindness charity
May 22, 2006A UK blindness charity says patients are being denied a new drug because PCTs are exploiting a delay in NICE's …
Medicom expands into branding
May 19, 2006Business Services
PR and medical education group Medicom has launched a new consultancy that offers product and corporate branding services.The new division, …
Industry experts to advise Northwick Park investigation
May 19, 2006Research and Development
Experts from the UK's pharmaceutical and biotech industries are to assist the inquiry into the Northwick Park drug trial, which …
AstraZeneca’s
May 18, 2006Research and Development, Sales and Marketing
AstraZeneca is to buy Cambridge Antibody Technology for 702 million pounds in a bid to expand its reach into biotechnology.Cambridge …
Seroxat raises suicide risk in young adults, says GSK
May 17, 2006Sales and Marketing
GlaxoSmithKline says new analyses of its antidepressant Seroxat show the drug raises the risk of suicidal behaviour in young adults.The …
Blair speaks out against animal extremists
May 15, 2006Sales and Marketing
Prime Minister Tony Blair has spoken out against animal rights activists, saying it was time for the 'silent majority' to …
UK government declares ‘end to Prozac nation’
May 12, 2006Sales and Marketing
People suffering from depression in the UK have been promised easier access to counselling and 'talking therapies' by the government, …
Pfizer’s smoking cessation drug approved
May 12, 2006Sales and Marketing
Chantix, a new drug which could help smoker's kick their habit and boost Pfizer's sales by billions has been approved …
Kendle spends $215 million to become major clinical research player
May 12, 2006Research and Development
Kendle is to spend $215 million on buying the business of rivals Charles River, a move which the companys leaders …
Merck buys antibody design specialists
May 10, 2006Research and Development
Merck is to buy a pioneering biotech company, which discovers new monoclonal antibodies and then re-engineers them to make them …
Scotland clears Femara for early breast cancer
May 9, 2006Sales and Marketing
Femara has been recommended for use in Scotland to prevent breast cancer returning after surgery, prompting its manufacturers and stakeholders …
Janssen-Cilag submits new schizophrenia drug
May 8, 2006Sales and Marketing
A new slow-release drug for schizophrenia has been filed for approval in Europe by Jannsen-Cilag, the manufacturers of top-selling Risperdal.Paliperidone …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
